Programmed Cell Death 1 Ligand 2 Protein
"Programmed Cell Death 1 Ligand 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A costimulatory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 RECEPTOR. It is closely-related to CD274 antigen; however, its expression is restricted to DENDRITIC CELLS and activated MACROPHAGES.
| Descriptor ID |
D061027
|
| MeSH Number(s) |
D12.776.467.150.800 D12.776.543.095.800 D23.050.301.285.800 D23.529.168.800
|
| Concept/Terms |
Programmed Cell Death 1 Ligand 2 Protein- Programmed Cell Death 1 Ligand 2 Protein
- CD273 Antigen
- Antigen, CD273
- PD-L2 Ligand
- Ligand, PD-L2
- PD L2 Ligand
- B7-DC Ligand
- B7 DC Ligand
- Ligand, B7-DC
- Antigens, CD273
- CD273 Antigens
- B7-DC Antigen
- Antigen, B7-DC
- B7 DC Antigen
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Ligand 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Ligand 2 Protein".
This graph shows the total number of publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in this website by year, and whether "Programmed Cell Death 1 Ligand 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in Profiles.
-
Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020 11; 23(6):951-960.
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
-
Fibrinogen cleavage products and Toll-like receptor 4 promote the generation of programmed cell death 1 ligand 2-positive dendritic cells in allergic asthma. J Allergy Clin Immunol. 2018 08; 142(2):530-541.e6.
-
Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017 Mar; 54:99-109.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
-
Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016 05; 30(3):189-200.
-
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta. 2016 Jan; 1865(1):58-71.
-
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
-
T cell-dependent IgM memory B cells generated during bacterial infection are required for IgG responses to antigen challenge. J Immunol. 2013 Aug 01; 191(3):1240-9.